169 related articles for article (PubMed ID: 35191542)
1. How I manage myeloproliferative neoplasm-unclassifiable: Practical approaches for 2022 and beyond.
McLornan DP; Hargreaves R; Hernández-Boluda JC; Harrison CN
Br J Haematol; 2022 May; 197(4):407-416. PubMed ID: 35191542
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.
Hargreaves R; Harrison CN; McLornan DP
Curr Res Transl Med; 2022 Jul; 70(3):103338. PubMed ID: 35217310
[TBL] [Abstract][Full Text] [Related]
3. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.
Pizzi M; Croci GA; Ruggeri M; Tabano S; Dei Tos AP; Sabattini E; Gianelli U
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830822
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study.
Crane GM; Geyer JT; Thakral B; Wang SA; Wool GD; Li KD; Davis AR; Boiocchi L; Bosler D; Bueso-Ramos CE; Arber DA; George TI; Bagg A; Hasserjian RP; Orazi A; Hsi ED; Rogers HJ
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38597584
[TBL] [Abstract][Full Text] [Related]
5. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
6. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey.
Ellis MH; Lavi N; Vannucchi A; Harrison C
Thromb Res; 2014 Aug; 134(2):251-4. PubMed ID: 24842684
[TBL] [Abstract][Full Text] [Related]
7. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
8. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Koschmieder S
Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
De Stefano V; Finazzi G; Barbui T
Blood Cancer J; 2018 Jun; 8(7):65. PubMed ID: 29946112
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.
Deschamps P; Moonim M; Radia D; Curto-Garcia N; Woodley C; Bassiony S; O'Sullivan J; Harrington P; Raj K; Francis Y; Kordasti S; Ali S; Harrison CN; McLornan DP
Br J Haematol; 2021 May; 193(4):792-797. PubMed ID: 33751548
[TBL] [Abstract][Full Text] [Related]
12. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
[TBL] [Abstract][Full Text] [Related]
13. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
15. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
16. Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT.
McLornan DP; Malpassuti V; Lippinkhof-Kozijn A; Potter V; Beelen D; Bunjes D; Sengeloev H; Radujkovic A; Passweg J; Chalandon Y; Kröger N; Wulf GG; Johansson JE; Ciceri F; Bornhäuser M; Holler E; Guffroy B; Martin S; Neubauer A; Gramatski M; Robin M; Iacobelli S; Hayden P; Hernández Boluda JC; Czerw T; Yakoub-Agha I
Br J Haematol; 2020 Aug; 190(3):437-441. PubMed ID: 32108327
[TBL] [Abstract][Full Text] [Related]
17. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Barbui T; Thiele J; Gisslinger H; Kvasnicka HM; Vannucchi AM; Guglielmelli P; Orazi A; Tefferi A
Blood Cancer J; 2018 Feb; 8(2):15. PubMed ID: 29426921
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
Tefferi A; Skoda R; Vardiman JW
Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
[TBL] [Abstract][Full Text] [Related]
19. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'.
Mehta D; Alimam S; McLornan DP; Henry JA; Ahmed S; Ghosh AK; Tyebally S; Walker JM; Patel R; Amerikanou R; O'Nions J; Wilson AJ; Lambert J; Sekhar M; Chen D
Curr Res Transl Med; 2024 Mar; 72(1):103420. PubMed ID: 38262189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
